Drug Profile
Research programme: cyclo-oxygenase-2 inhibitors - Roche Bioscience
Alternative Names: Research programme: COX-2 inhibitors - RocheLatest Information Update: 08 Nov 2006
Price :
$50
*
At a glance
- Originator Roche Palo Alto LLC
- Class
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 08 Nov 2006 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 14 Aug 2001 No-Development-Reported for Inflammation in USA (Unknown route)
- 12 Aug 1998 New profile